🌎 30+ NEW AI-picked share strategies for exciting international marketsUnlock Global AI Picks

Bayer says 2024 sales of prostate cancer drug above $1 billion

Published 21/03/2024, 12:07
© Reuters. The 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical industry in Leverkusen, Germany, September 23, 2023. REUTERS/Wolf

© Reuters. The 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical industry in Leverkusen, Germany, September 23, 2023. REUTERS/Wolf

BAYGN
0.61%

FRANKFURT (Reuters) - Bayer (ETR:BAYGN) on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which is playing a bigger role for the drugmaker's growth prospects after the failure of a promising anti-blood-clotting therapy.

"Nubeqa ... is set for continued growth in prostate cancer and is on track to reach blockbuster status this year – only five years after first indication launch," it said in a statement.

Blockbuster is an industry term for drugs with at least $1 billion in annual sales.

Bayer chalked up sales of Nubeqa, jointly developed with Finnish drugmaker Orion, of 869 million euros ($948 million) last year and the company has previously projected annual peak sales potential of more than three billion euros.

Bayer confirmed that even though experimental anticoagulant asundexian failed last year to sufficiently prevent strokes in high-risk patients in a trial, another study known as Oceanic would continue.

Oceanic, to test the drug in patients who have already suffered a stroke, was "progressing rapidly", it added.

($1 = 0.9162 euros)

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Should you invest $2,000 in BAYGN right now?

With BAYGN making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed BAYGN alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including BAYGN, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is BAYGN poised for similar growth? Don't miss the opportunity to find out.

Reveal Undervalued Stocks Now

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.